Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease

QI Ruo-bing; YANG Yong-xiu; JIANG Hui-quan; YIN Xiao-wen; CHEN Bin-hua; FEI Jian-hui; LEI Lan-ying; ZHANG Xue-ping

doi:10.16766/j.cnki.issn.1674-4152.002181

Volume 19 Issue 11

Nov. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Chinese Journal of General Practice > 2021 > 19(11): 1843-1845,1915

QI Ruo-bing, YANG Yong-xiu, JIANG Hui-quan, YIN Xiao-wen, CHEN Bin-hua, FEI Jian-hui, LEI Lan-ying, ZHANG Xue-ping. Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1843-1845,1915. doi: 10.16766/j.cnki.issn.1674-4152.002181

Citation:

QI Ruo-bing, YANG Yong-xiu, JIANG Hui-quan, YIN Xiao-wen, CHEN Bin-hua, FEI Jian-hui, LEI Lan-ying, ZHANG Xue-ping. Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1843-1845,1915. doi: 10.16766/j.cnki.issn.1674-4152.002181

Citation:

QI Ruo-bing, YANG Yong-xiu, JIANG Hui-quan, YIN Xiao-wen, CHEN Bin-hua, FEI Jian-hui, LEI Lan-ying, ZHANG Xue-ping. Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1843-1845,1915. doi: 10.16766/j.cnki.issn.1674-4152.002181

PDF( 1130 KB)

Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease

doi: 10.16766/j.cnki.issn.1674-4152.002181

Department of Gerontology, Hangzhou Seventh People's Hospital, Hangzhou, Zhejiang 310013, China

Funds:

2018KY610

Received Date: 2020-12-11

Abstract

Abstract

Objective To analyse the efficacy and safety of donepezil and memantine combined with risperidone in the treatment of behavioural and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD). Methods A total of 150 patients with AD and BPSD who were admitted to Hangzhou Seventh People's Hospital from January 2017 to June 2019 were randomly divided into risperidone group (group A), risperidone+donepezil group (group B) and risperidone+donepezil+memogen group (group C) through a random number method, with 50 patients in each group. Before treatment, the positive and negative syndrome scale (PANSS), MOCA scale, blood sugar, triglyceride and cholesterol were recorded. Twelve weeks after treatment, the PANSS, MOCA scale, treatment emergent symptom scale (TESS), blood sugar, triglyceride, cholesterol test of the three groups were compared, with special attention to PANSS, MOCA scale, blood glucose, blood lipids and adverse reactions. Results After treatment, the MOCA and PANSS scores of group C patients were significantly improved compared with those of the other two groups. MOCA score of group A [(14.86±3.78) points], group B [(16.94±3.57) points] and group C [(19.10±3.73) points], the difference was statistically significant (F=9.858, P < 0.05). PANSS scores were (110.52±11.55) points in group A, (99.96±8.47) points in group B and (86.14±5.48) points in group C, and the difference was statistically significant (F=94.100, P < 0.05). The incidence of adverse reactions was lower in group C than that in the other two groups, and the results were statistically significant. After treatment, the improvement of blood glucose, blood lipid, TESS and risperidone dosage in group C was more obvious than that in groups A and B. Conclusion Risperidone+donepezil group and risperidone+donepezil+memantine groups have better cognitive function improvement after treatment of BPSD, less side effects, reduced dose of risperidone drug treatment and improved quality of life.
- Alzheimer disease,
- Risperidone,
- Behavioural and psychological symptoms of dementia,
- Memantine

FullText(HTML)

References(15)

References

[1]	万素馨, 方伟. 阿尔茨海默病的治疗药物作用机制研究进展[J]. 现代药物与临床, 2018, 33(12): 3406-3410. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW201812070.htm
[2]	彭也, 朱天碧, 张钊, 等. 阿尔茨海默病的免疫调控研究进展[J]. 中国药理学通报, 2019, 35(4): 445-451. doi: 10.3969/j.issn.1001-1978.2019.04.001
[3]	杜荣蓉, 曲连悦, 孙珊珊, 等. 阿尔茨海默病的药物治疗研究现状[J]. 中国临床药理学杂志, 2019, 35(5): 489-492. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201905024.htm
[4]	周源源. 阿尔茨海默病的流行病学、发病危险因素、治疗及早期筛查研究进展[J]. 内科, 2019, 14(6): 690-692. https://www.cnki.com.cn/Article/CJFDTOTAL-NKYT201906019.htm
[5]	王晓珍, 王蓉. 阿尔茨海默病的药物治疗及研发进展[J]. 中国新药杂志, 2019, 28(24): 2960-2964. doi: 10.3969/j.issn.1003-3734.2019.24.007
[6]	程喆歆, 梁庆成, 吴云, 等. 阿尔茨海默病的发病机制及药物治疗的研究进展[J]. 现代生物医学进展, 2017, 17(10): 1981-1985. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201710049.htm
[7]	段玉梅, 文国强. 阿尔茨海默病危险因素及预防策略的研究进展[J]. 海南医学, 2020, 31(2): 224-227. doi: 10.3969/j.issn.1003-6350.2020.02.025
[8]	杨柳. 脑兴奋性突触后NMDA受体信号转导复合物[J]. 国外医学(生理、病理科学与临床分册), 2005, 2(3): 207-210. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB200503005.htm
[9]	王菁. 多奈哌齐联合尼莫地平治疗阿尔茨海默症临床效果[J]. 慢性病学杂志, 2020, 21(2): 177-179. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO202002007.htm
[10]	宋博雅. 阿尔兹海默症发病机制的研究进展[J]. 西安文理学院学报(自然科学版), 2020, 23(4): 77-79, 92. doi: 10.3969/j.issn.1008-5564.2020.04.016
[11]	COLOM-CADENA M, SPIRES-JONES T, ZETTERBERG H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease[J]. Alzheimer's Res Ther, 2020, 12(1): 21. doi: 10.1186/s13195-020-00588-4
[12]	何志军, 陈杰瑞, 薛华, 等. 阿尔茨海默症与2型糖尿病的共病机制及硒与钒的作用[J]. 生命科学, 2020, 32(6): 597-605. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX202006011.htm
[13]	赵丽萍, 缪林清, 蒋鹭莲, 等. 针刺改善阿尔茨海默病氧化应激机制的研究现状与思考[J]. 世界科学技术-中医药现代化, 2020, 22(8): 2670-2678. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202008012.htm
[14]	胡建庆, 赵俊, 卢梦晗, 等. "通督启神"针法治疗阿尔茨海默病的理论探讨[J]. 世界科学技术-中医药现代化, 2020, 22(8): 2634-2640. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202008006.htm
[15]	邱聪龙, 张怡, 陈寿林, 等. 不同程度阿尔茨海默病患者血脂水平的研究[J]. 中华全科医学, 2020, 18(12): 2043-2046. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202012019.htm

Relative Articles

[1]	ZHANG Lie, LING Yingchun, GAO Gangmei. Efficacy of donepezil combined with cognitive rehabilitation in treating Alzheimer's disease based on near-infrared brain function detection[J]. Chinese Journal of General Practice, 2024, 22(11): 1872-1875. doi: 10.16766/j.cnki.issn.1674-4152.003753
[2]	ZHU Ruhuang, ZHENG Huihui, WANG Wanhui, WANG Zhen. Effect of action research-based Montessori feeding training on feeding behavior of Alzheimer's disease patients[J]. Chinese Journal of General Practice, 2024, 22(4): 605-608. doi: 10.16766/j.cnki.issn.1674-4152.003461
[3]	PAN Jianbo, XIE Weigen, CHENG Lingying, TANG Zhixian, PAN Yiqun. Correlation analysis between benefit finding and abuse tendency of family caregivers of patients with Alzheimer's disease[J]. Chinese Journal of General Practice, 2023, 21(8): 1332-1334. doi: 10.16766/j.cnki.issn.1674-4152.003116
[4]	LI Xiaoxiong, LI Jinping, HUANG Jie, MA Jingjing, HOU Mingliang, MA Linqiu, WANG Congguo, ZHOU Huadong. Analysis of circRNA and mRNA expression profiles in Alzheimer's disease mice treated with islet amyloid polypeptide[J]. Chinese Journal of General Practice, 2023, 21(7): 1101-1104. doi: 10.16766/j.cnki.issn.1674-4152.003059
[5]	YIN Shuqin, WANG Lina. A study on protective factors related to the early stages of Alzheimer' s disease[J]. Chinese Journal of General Practice, 2023, 21(4): 565-567. doi: 10.16766/j.cnki.issn.1674-4152.002931
[6]	HUANG Jin, ZHU Cheng. Effects of paliperidone sustained-release tablets combined with aripiprazole on psychotic symptoms, cognitive function and prolactin in schizophrenia[J]. Chinese Journal of General Practice, 2022, 20(10): 1688-1690. doi: 10.16766/j.cnki.issn.1674-4152.002680
[7]	LI Wei-ying, LIN Qing, FU Pan. Expression and significance of plasma Aβ1-40, blood lipid and inflammatory indexes in Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(12): 2048-2050, 2118. doi: 10.16766/j.cnki.issn.1674-4152.002233
[8]	HAN Guang-hong, PANG Xiao-li, SUN Hui-li, WANG Wei. Reporting quality evaluation of meta-analyses on cognitive interventions for Alzheimer's disease in China[J]. Chinese Journal of General Practice, 2021, 19(11): 1946-1950. doi: 10.16766/j.cnki.issn.1674-4152.002208
[9]	ZHAO Ping, LI Xin, CUI Jing, XIA Xiaoshuang, TIAN Wenjie. Effect of Ginkgo biloba extract on bFGF/Notch1 pathway in hippocampus of rats models with Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(8): 1283-1286. doi: 10.16766/j.cnki.issn.1674-4152.002041
[10]	HU Chen-ling, ZHANG Xue-ping, YANG Rong-mei, ZHOU Fen-fang. Serum complement C5a levels and its association with inflammatory factors in patients with Alzheimer's disease[J]. Chinese Journal of General Practice, 2020, 18(5): 760-762. doi: 10.16766/j.cnki.issn.1674-4152.001349
[11]	QIU Cong-long, ZHANG Yi, CHEN Shou-lin, SHAO Li, ZOU Chen-jun, ZHANG Ying-zhong, ZHOU Dong-sheng. A study of serum lipid levels in patients with different degrees of Alzheimer’s disease[J]. Chinese Journal of General Practice, 2020, 18(12): 2043-2046. doi: 10.16766/j.cnki.issn.1674-4152.001684
[12]	HUA Hao-shui, SHAO Jian-feng, LU Yuan-xin, LIAO Zheng-luan. Therapeutic effect of small dose of ziprasidone combined donepezil hydrochloride on Alzheimer's disease and its effect on glucose and lipid metabolism in patients[J]. Chinese Journal of General Practice, 2019, 17(11): 1860-1863. doi: 10.16766/j.cnki.issn.1674-4152.001075
[14]	TANG Chun-xia, CHEN Zhe-li, XU Chun-yun. Application of multidisciplinary collaborative nursing mode in Alzheimer's disease[J]. Chinese Journal of General Practice, 2019, 17(1): 150-153. doi: 10.16766/j.cnki.issn.1674-4152.000625
[15]	QIU Ling-shan, TAO Ping-yu, SUN Guo-qing, ZHANG Xue-ping, WANG Sheng-dong. Value of mitochondrial dynamic protein 1 in the early diagnosis of Alzheimer's disease[J]. Chinese Journal of General Practice, 2019, 17(4): 561-563,704. doi: 10.16766/j.cnki.issn.1674-4152.000734
[16]	JIANG Hong-xia, LIN Yong, FEI Yu-e, TANG Chen-dong, PU Zheng-ping, CHANG Sheng. Correlation between the severity of Alzheimer's disease and the levels of serum copper,iron and zinc[J]. Chinese Journal of General Practice, 2017, 15(5): 827-829,907. doi: 10.16766/j.cnki.issn.1674-4152.2017.05.030
[17]	LIN Yong, SHEN Jian-gen, LI Guo-rong, ZHANG Xiao-ling, PU Zheng-ping, JIN Wei-dong, WANG Lian-e, HUANG Man-li. Changes of levels of serum ceruloplasmin in patients with Alzheimer's disease[J]. Chinese Journal of General Practice, 2017, 15(10): 1718-1721. doi: 10.16766/j.cnki.issn.1674-4152.2017.10.024
[18]	HE Wen-wen. The analysis of related factors about Alzheimer's disease patients of aspiration/suffocation[J]. Chinese Journal of General Practice, 2017, 15(4): 708-711. doi: 10.16766/j.cnki.issn.1674-4152.2017.04.049
[19]	LIANG Xiao-song. Application evaluation of Paliperidone combined with sodium valproate on mental disorders aggressive behavior due to brain injury[J]. Chinese Journal of General Practice, 2016, 14(3): 399-400,434. doi: 10.16766/j.cnki.issn.1674-4152.2016.03.020
[20]	HUANG Lei, QIAN Jian-jun, TIAN Guo-qiang, JIANG Hai-chao, FENG Hong. Clinical efficacy of different drug therapy combined with risperidone and cognitive-behavioral in the treatment of residual schizophrenia[J]. Chinese Journal of General Practice, 2016, 14(11): 1816-1819. doi: 10.16766/j.cnki.issn.1674-4152.2016.11.008

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	徐丽霞，赖利丹，王成炯，马颖超. 聪脑汤加减治疗老年痴呆患者的疗效观察及对认知功能、生活能力的影响. 中国中医药科技. 2025(01): 67-71 .
2.	刘景妨，刘景艳，宋广文. 盐酸多奈哌齐联合美金刚对阿尔茨海默病患者认知功能的影响. 中国基层医药. 2024(01): 29-33 .
3.	陈曦，谢茹韵. 美金刚、多奈哌齐联合支持性护理干预对阿尔茨海默病患者精神症状、认知功能的影响. 现代医学与健康研究电子杂志. 2024(08): 116-118 .
4.	李颖，李慧，李海平，李薇. 美金刚联合多奈哌齐治疗阿尔茨海默病患者的效果. 中国民康医学. 2024(13): 37-40 .
5.	唐斌，冯冲，张园芳，许宁海，熊富先. 利培酮联合盐酸多奈哌齐治疗阿尔茨海默病的疗效. 临床合理用药. 2024(29): 51-54 .
6.	郑晓芬，罗雪文. 参蓉补脑汤联合替米沙坦治疗高血压合并老年痴呆患者的效果观察. 心血管病防治知识. 2024(16): 64-67 .
7.	王有彬. 喹硫平联合多奈哌齐治疗阿尔茨海默病对认知能力及精神症状的影响. 大医生. 2023(07): 51-53 .
8.	王映芬，周铭，王映娥. 盐酸多奈哌齐联合丁苯酞对血管性痴呆患者脑血流变化和认知功能及神经电生理的影响. 中国临床研究. 2023(03): 370-374 .
9.	张莹莹，周义锋. 不同剂量多奈哌齐联合美金刚治疗阿尔茨海默病行为、精神失智有效性研究. 河北北方学院学报(自然科学版). 2023(08): 48-51+53 .
10.	任虹，孙俊伟. 利培酮联合盐酸多奈哌齐对阿尔茨海默病患者行为精神症状的治疗效果. 中国实用医刊. 2022(10): 110-113 .
11.	曹靖宜，唐权，王河钰，张严. 基于突触再生相关蛋白(F-actin)筛选抗阿尔茨海默病药物先导化合物的研究. 中央民族大学学报(自然科学版). 2022(03): 16-24 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (477) PDF downloads(8)

Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease

doi: 10.16766/j.cnki.issn.1674-4152.002181